Head-to-head · WeighScore
Hormonally Balanced vs MyStart Health
The verdict
MyStart Health takes it — 67.1/100 to 56.4/100.
MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Hormonally Balanced | MyStart Health |
|---|---|---|
| WeighScore | 56.4/100 | 67.1/100 |
| Grade | C | C |
| Scorecard rank | #412 | #168 |
| Semaglutide | Not disclosed | $299/mo (all doses, compounded) |
| Tirzepatide | Not disclosed | $299/mo (all doses, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #412 · C
Strengths
- Physician-led women's hormone clinic with concierge model
- Nationwide telehealth availability
- Semaglutide integrated with hormone care for women
- Named physician (Dr. Zachareas) oversees prescriptions
Where it loses points
- No pricing published online; must call or submit a form
- Weight loss is secondary to menopause/hormone focus
- Semaglutide only; no tirzepatide listed
- Compounded vs brand formulation not disclosed
Graded #168 · C
Strengths
- Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
- Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
- 24/7 care team access with unlimited clinician messaging included
- LegitScript certified
- Clear Section 503A compounding disclosure on every landing page
Where it loses points
- Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
- Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
- Very new company (incorporated May 2024) with a limited track record
- Pharmacy partners not named, so 503A compliance can't be independently verified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.